BEIJING, Nov. 6, 2024 /PRNewswire/ — MEGAROBO, a leading provider of advanced productivity tools for life sciences, has recently unveiled the CellVue™ T2000 high-content cell imaging system. The new cell imaging system is more than a digital microscope, featuring a high-sensitivity CMOS imaging camera that seamlessly integrates automated multi-color fluorescence imaging with quantitative data analysis. The system enables in-depth exploration of the multi-dimensional characteristics of individual cells in biological samples, serving a wide range of applications, from basic research to drug discovery and preclinical trials. The technology provides scientists with rapid, high-resolution cell imaging and comprehensive, accurate data support.
As the latest breakthrough in life science research tools, MEGAROBO’s proprietary CellVue™ T2000 builds upon the strengths of traditional high-content imaging systems while achieving remarkable strides in imaging speed, configurability, and functional versatility. With unprecedented efficiency, the system meets the urgent need for high-throughput imaging in complex experimental scenarios, enhancing data stability, reliability, and experimental reproducibility. Furthermore, the solution offers extensive upgrade options for cytotoxicity studies, cell painting and 3D sample studies, ensuring optimal configurations that address the specific needs of different research teams.
In addition, the CellVue™ T2000 has been fully incorporated into AutoBio™, the laboratory automation system developed by MEGAROBO. This integration enables a fully automated workflow from cell seeding, passaging and drug delivery to image detection and analysis.
“Whether examining the fine structure of the cytoskeleton and nucleus or the spatial relationships between functional proteins, the system can deliver high-definition images and precise data,” said Daniel Huang, Founder and CEO of MEGAROBO. “The capability allows researchers to gain deeper insights into cell biology phenomena and mechanisms. With the CellVue™ T2000 as a starting point, MEGAROBO will continue to facilitate technological innovation in the life sciences sector, inspiring deeper exploration into uncharted territories.”
With a global footprint spanning China, the U.S., Europe, and Southeast Asia, MEGAROBO has solidified its position as a leading force in intelligent automation and life sciences innovation worldwide.
About MEGAROBO
Founded in 2016, MEGAROBO is a science and technology company specializing in providing advanced production tools for life sciences, drug discovery, clinical diagnostics and applied chemistry industries. MEGAROBO has closed the Series C financing round, securing long-term support from key investors including WuXi AppTec, Bosch, Sino Biological, Goldman Sachs Asset Management, Asia Investment Capital, Jiyuan Capital, Sinovation Ventures, Joy Capital, MPCi and Pavilion Capital.
SOURCE MEGAROBO
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…